Malat1 Lncrna
Malat1 Lncrna - Related Videos
02:39
lncRNA - Long Non-coding RNAs
0 Views •
2020
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
02:39
lncRNA - Long Non-coding RNAs
0 Views •
2023
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
06:13
Colony Formation Assay Detecting the Proliferative Capacity of LncRNA-knockdown Osteosarcoma Cells
0 Views •
2026
This experimental protocol provides a stable, cost-effective, and efficient method that combines lncRNA knockdown with colony-forming assays to quantify the effect of lncRNA on osteosarcoma cell proliferation.
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
0 Views •
Cited by 17 •
2018
This manuscript describes the synthesis of a single-wall carbon nanotube (SWCNT)-conjugated MALAT1 antisense gapmer DNA oligonucleotide (SWCNT-anti-MALAT1), which demonstrates the reliable delivery of the SWCNT and the potent therapeutic effect of anti-MALAT1 in vitro and in vivo. Methods used for synthesis, modification, conjugation, and injection of SWCNT-anti-MALAT1 are described.
09:30
A UV-Based ChIRP Method For The Verifiable Identification of Proteins That Directly Interact With LncRNA: From Cultured Cells To Mouse Testis
0 Views •
2026
A UV-based ChIRP method to identify direct lncRNA-protein interactions.
FAQs
Its nuclear localization places it near nuclear speckles, RNA-processing factors, and chromatin-associated proteins. Through these interactions, MALAT1 can influence alternative splicing, which changes how transcripts are processed, as well as transcription and broader cell-state programs. These mechanisms provide a molecular basis for examining how altered MALAT1 expression may affect cancer-cell behavior.
MALAT1 has a context-dependent role, meaning its effects can vary with the malignancy and cellular state being studied. Altered expression has been associated with proliferation, invasion, metastasis, therapy response, and prognosis across multiple cancers, but these links do not imply an identical mechanism in every tumor. Cancer-specific investigation is therefore important.
Interactions with chromatin-associated proteins connect MALAT1 to regulatory environments that influence transcription. This relationship complements its association with RNA-processing factors, allowing researchers to consider effects at both transcript processing and gene-regulation levels. Studying these interactions can help explain how MALAT1 contributes to changes in cell-state programs relevant to tumor progression.
Common approaches described for MALAT1 research include expression profiling, loss-of-function experiments, and RNA-targeting strategies. Expression profiling assesses altered levels, while loss-of-function studies test what happens when its activity is reduced. RNA-targeting approaches examine whether changing the molecule can modify cancer-relevant phenotypes or support its evaluation as a therapeutic target.
Researchers compare MALAT1 expression with cancer-associated features such as tumor-cell proliferation, invasion, metastasis, therapy response, or patient prognosis. Consistent relationships may support biomarker development, but interpretation must remain specific to the malignancy and study context. Its reported association with prognosis also makes MALAT1 relevant to investigations of clinically meaningful disease patterns.
MALAT1 is studied in precision oncology because its dysregulation may relate to tumor behavior and treatment response in a context-dependent manner. Researchers investigate whether expression patterns can help characterize patients or tumors and whether RNA-targeting strategies can provide therapeutic leverage. These studies connect molecular regulation with individualized assessment of cancer biology and treatment.